Chugai partnered with Phylo to deploy agentic AI in drug discovery.
The goal is earlier, more precise target selection.
This supports R&D productivity but does not fix pricing pressures.
What happened
Chugai Pharmaceutical began rolling out an agentic AI platform across its drug discovery workflow and partnered with Phylo to apply the technology to single-cell data, human genetics, and disease biology.
Why it matters
The move leverages Chugai's solid profitability to fund AI-driven R&D, aiming for earlier and more precise target selection. It addresses short-term concerns about R&D productivity and diversification, but its impact on sales dependence on Hemlibra and Actemra remains unclear and does not materially change near-term patent or pricing risks.
What to watch
A consensus forecast sees fair value at ¥9,687, implying 38% upside from the current price. More optimistic analysts already model sales near ¥1.935 trillion and profit around ¥810 billion by 2029, before the Phylo deal.
Ask the AI about this article →
Chugai's partnership with Phylo comes as the company faces maturation of its key products. By embedding agentic AI into discovery, Chugai aims to build a stronger pipeline before patents expire. The deal aligns with recent regulatory filings for Tecentriq and Enspryng expansions, linking AI research to late-stage assets. However, the near-term sales concentration in Hemlibra and Actemra remains a risk, and the AI push does not address pricing pressure. Investor expectations vary widely, with fair value estimates ranging from about ¥7,200 to ¥9,687, showing divergent views on AI's impact.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
China has published its first national standard for liquid cooling in data centers, responding to AI racks app…
OpenAI announced on August 28 that it will terminate its model access contract with AI coding tool Cursor, pro…
Bernstein analysts say AI is creating a memory bottleneck, with demand expanding from high-bandwidth memory (H…
OpenAI CEO Sam Altman said in a Time magazine interview that he thinks "it is a good time to slow down" AI mod…
Nvidia's earnings on Wednesday shifted the narrative, showing its advantage extends beyond GPUs to the systems…
Merck & Company, Amgen, and Johnson & Johnson are highlighted as AI-linked healthcare stocks that have outperf…
